Appendix 4E and Annual Report
Filed with ASX · · 114 pages · English
Summary by 6ix AI
The report highlights significant advancements in its azer-cel program, an allogeneic CAR T cell therapy, which has shown promising clinical outcomes in treating blood cancers. Imugene reported a loss for the year, reflecting improvements in cost management and a focus on advancing its clinical pipeline. The company has also strengthened its leadership team and secured funding to support ongoing development and clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Imugene
- Imugene Capital Raising Presentation
- Imugene Completes $22.5M Placement and c.$15M SPP
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
- Two Additional Complete Responses in azer-cel Ph1b trial
- Notice of Extraordinary General Meeting/Proxy Form
Later from Imugene
- Final Share Purchase Plan Allotment
- S&P DJI Announces September 2025 Quarterly Rebalance
- Strategic Collaboration with JW Therapeutics
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
- FDA Supports Strategy Toward Registration for Azer-cel
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene